|
Status |
Public on Apr 24, 2019 |
Title |
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation(s) |
31969702 |
|
Submission date |
Apr 24, 2019 |
Last update date |
Feb 19, 2020 |
Contact name |
Xin Lu |
E-mail(s) |
[email protected]
|
Phone |
847-937-7942
|
Organization name |
Abbvie
|
Department |
Oncology Discovery
|
Street address |
1 North Waukegan Rd
|
City |
North Chicago |
State/province |
IL |
ZIP/Postal code |
60064 |
Country |
USA |
|
|
Platforms (1) |
GPL21290 |
Illumina HiSeq 3000 (Homo sapiens) |
|
Samples (20)
|
GSM3319571 |
LNCaP_DHT_DMSO rep2 |
GSM3319572 |
LNCaP_DHT_ENZ rep1 |
GSM3319573 |
LNCaP_DHT ENZ rep2 |
GSM3319574 |
LNCaP_DHT_ABBV-075 rep1 |
GSM3319575 |
LNCaP_DHT_ABBV-075 rep2 |
GSM3319576 |
LNCaP_DHT_ABBV-744 rep1 |
GSM3319577 |
LNCaP_DHT_ABBV-744 rep2 |
GSM3734476 |
c114416_rnaseq_uziel_22rv1_13: 22RV1_EtOH_DMSO rep1 |
GSM3734477 |
c114416_rnaseq_uziel_22rv1_14: 22RV1_EtOH_DMSO rep2 |
GSM3734478 |
c114416_rnaseq_uziel_22rv1_15: 22RV1_DHT_DMSO rep1 |
GSM3734479 |
c114416_rnaseq_uziel_22rv1_16: 22RV1_DHT_DMSO rep2 |
GSM3734480 |
c114416_rnaseq_uziel_22rv1_17: 22RV1_DHT_ENZ rep1 |
GSM3734481 |
c114416_rnaseq_uziel_22rv1_18: 22RV1_DHT ENZ rep2 |
GSM3734482 |
c114416_rnaseq_uziel_22rv1_19: 22RV1_DHT_ABBV-075 rep1 |
GSM3734483 |
c114416_rnaseq_uziel_22rv1_20: 22RV1_DHT_ABBV-075 rep2 |
GSM3734484 |
c114416_rnaseq_uziel_22rv1_21: 22RV1_DHT_ABBV-744 rep1 |
GSM3734485 |
c114416_rnaseq_uziel_22rv1_22: 22RV1_DHT_ABBV-744 rep2 |
|
This SuperSeries is composed of the following SubSeries: |
GSE118152 |
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (LNCaP RNA-seq) |
GSE130247 |
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (22RV1 RNA-seq) |
|
Relations |
BioProject |
PRJNA534480 |